127 related articles for article (PubMed ID: 8911119)
1. Multiple forms of TGF-beta 1 in breast tissues: a biologically active form of the small latent complex of TGF-beta 1.
Baillie R; Coombes RC; Smith J
Eur J Cancer; 1996 Aug; 32A(9):1566-73. PubMed ID: 8911119
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen.
Benson JR; Wakefield LM; Baum M; Colletta AA
Br J Cancer; 1996 Aug; 74(3):352-8. PubMed ID: 8695348
[TBL] [Abstract][Full Text] [Related]
3. The first stage of transforming growth factor beta1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3).
Maeda S; Dean DD; Gomez R; Schwartz Z; Boyan BD
Calcif Tissue Int; 2002 Jan; 70(1):54-65. PubMed ID: 11907708
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor beta secretion from primary breast cancer fibroblasts.
van Roozendaal CE; Klijn JG; van Ooijen B; Claassen C; Eggermont AM; Henzen-Logmans SC; Foekens JA
Mol Cell Endocrinol; 1995 Apr; 111(1):1-6. PubMed ID: 7649348
[TBL] [Abstract][Full Text] [Related]
5. The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer.
Yoo YA; Kim YH; Kim JS; Seo JH
Biochim Biophys Acta; 2008 Mar; 1783(3):438-47. PubMed ID: 18164268
[TBL] [Abstract][Full Text] [Related]
6. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta.
Odekon LE; Blasi F; Rifkin DB
J Cell Physiol; 1994 Mar; 158(3):398-407. PubMed ID: 8126064
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer.
Thompson AM; Kerr DJ; Steel CM
Br J Cancer; 1991 Apr; 63(4):609-14. PubMed ID: 2021547
[TBL] [Abstract][Full Text] [Related]
8. Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy.
MacCallum J; Keen JC; Bartlett JM; Thompson AM; Dixon JM; Miller WR
Br J Cancer; 1996 Aug; 74(3):474-8. PubMed ID: 8695368
[TBL] [Abstract][Full Text] [Related]
9. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.
Arteaga CL; Koli KM; Dugger TC; Clarke R
J Natl Cancer Inst; 1999 Jan; 91(1):46-53. PubMed ID: 9890169
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
11. Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer.
Brandt S; Kopp A; Grage B; Knabbe C
Anticancer Res; 2003; 23(1A):223-9. PubMed ID: 12680217
[TBL] [Abstract][Full Text] [Related]
12. Effects of retinol on activation of latent transforming growth factor-beta by isolated osteoclasts.
Bonewald LF; Oreffo RO; Lee CH; Park-Snyder S; Twardzik D; Mundy GR
Endocrinology; 1997 Feb; 138(2):657-66. PubMed ID: 9003000
[TBL] [Abstract][Full Text] [Related]
13. 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells.
Koli K; Keski-Oja J
Cancer Res; 1995 Apr; 55(7):1540-6. PubMed ID: 7882362
[TBL] [Abstract][Full Text] [Related]
14. Latent transforming growth factor-beta complex in Chinese hamster ovary cells contains the multifunctional cysteine-rich fibroblast growth factor receptor, also termed E-selectin-ligand or MG-160.
Olofsson A; Hellman U; Ten Dijke P; Grimsby S; Ichijo H; Morén A; Miyazono K; Heldin CH
Biochem J; 1997 Jun; 324 ( Pt 2)(Pt 2):427-34. PubMed ID: 9182700
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the effects of TGF-beta 1 by activation of latent TGF-beta 1 and differential expression of TGF-beta receptors (T beta R-I and T beta R-II) in idiopathic pulmonary fibrosis.
Khalil N; Parekh TV; O'Connor R; Antman N; Kepron W; Yehaulaeshet T; Xu YD; Gold LI
Thorax; 2001 Dec; 56(12):907-15. PubMed ID: 11713352
[TBL] [Abstract][Full Text] [Related]
16. Secretion of transforming growth factor-beta isoforms by embryonic stem cells: isoform and latency are dependent on direction of differentiation.
Slager HG; Freund E; Buiting AM; Feijen A; Mummery CL
J Cell Physiol; 1993 Aug; 156(2):247-56. PubMed ID: 8344983
[TBL] [Abstract][Full Text] [Related]
17. The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study.
Murray PA; Gomm J; Ricketts D; Powles T; Coombes RC
Eur J Cancer; 1994; 30A(9):1218-22. PubMed ID: 7999402
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells.
Arteaga CL; Tandon AK; Von Hoff DD; Osborne CK
Cancer Res; 1988 Jul; 48(14):3898-904. PubMed ID: 3164252
[TBL] [Abstract][Full Text] [Related]
19. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen.
Boylan M; van den Berg HW; Lynch M
Ann Oncol; 1998 Feb; 9(2):205-11. PubMed ID: 9553667
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha enhances secretion of transforming growth factor beta2 in MCF-7 breast cancer cells.
Danforth DN; Sgagias MK
Clin Cancer Res; 1996 May; 2(5):827-35. PubMed ID: 9816237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
